(QTRX) Quanterix - Ratings and Ratios

Quanterix Corporation, a life sciences company, specializes in the development and marketing of digital immunoassay platforms designed to enhance precision health for life sciences research and diagnostics. The company operates globally, with a presence in North America, Europe, the Middle East, Africa, and the Asia Pacific. Its product portfolio includes the HD-X instrument, a high-precision protein detection platform; the SR-X instrument, which expands the application range of Simoa technology; and the SP-X instrument, utilizing Simoa planar array technology for multiplex chemiluminescent immunoassays. Quanterix offers a range of assays, including enzyme-based immunoassay components such as beads, capture and detector reagents, enzyme reagents, and substrate, as well as replacement parts, reagents, and antibodies. Additionally, the company provides contract research services, including sample testing, homebrew assay development, custom assay development, Lucent Diagnostic, and LDT testing services. Quanterix primarily serves the neurology, oncology, cardiology, infectious diseases, and inflammation sectors. Its customer base includes academic and governmental research laboratories, pharmaceutical, biotechnology, and contract research companies, with sales conducted through direct field sales, support organizations, and distributors or sales agents. Formerly known as Digital Genomics, Inc., the company changed its name to Quanterix Corporation in August 2007. Headquartered in Billerica, Massachusetts, Quanterix Corporation was incorporated in 2007.

Based on the provided data, Quanterix Corporation (NASDAQ:QTRX) is currently trading at $7.48 with a market capitalization of $475.90M USD. The stock has a price-to-book ratio of 1.14 and a price-to-sales ratio of 2.81, with a return on equity of -11.89%. The 20-day average volume is 646,299 shares. The stocks short-term trend indicators show the SMA 20 at $8.14, SMA 50 at $9.43, and SMA 200 at $12.53, with an ATR of 0.67.

3-month forecast: The stock is expected to remain under pressure as it trades below its SMA 20, SMA 50, and SMA 200, indicating a bearish trend. The ATR of 0.67 suggests moderate volatility, which could lead to further declines. However, the companys focus on precision health and its expanding product portfolio may provide some support. With a P/S ratio of 2.81 and a negative return on equity, investors may remain cautious. Overall, the outlook is bearish for the next quarter, with potential downside risks outweighing upside potential.